for a total of 6 months of perioperative systemic therapy for LARC. 12 The purpose of this study was to examine the population-based outcomes of patients with LARC treated with neoadjuvant CRT followed by surgery with or without AC using data from the
Search Results
Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta
J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman, and Hema Sundar
recommended for surveillance and treatment of late effects of surgery, RT, and chemotherapy in long-term survivors. Patients should be given a survivorship prescription to schedule follow-up with a multidisciplinary team. Fertility issues should be discussed
Parvin F. Peddi and Andrea Wang-Gillam
occlusion of splenic vein, portal vein, and SMV, with mild stranding near the SMA ( Figure 2 ). The decision was made to offer extended Whipple surgery with SMV and portal vein reconstruction in an attempt for a cure. The CA 19-9 level at this time was less
Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, Eric X. Chen, Raymond W. Jang, and Elena Elimova
-related death, respectively. 3 Surgery is the primary curative treatment modality, except for esophageal squamous cell carcinomas (SCCs), for which definitive chemoradiotherapy (CRT) can be considered. 4 , 5 Despite advances in surgical techniques, prognosis
David G. Pfister, Sharon Spencer, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Cristina P. Rodriguez, Sandeep Samant, David E. Schuller, Jatin P. Shah, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes
, and mucosal melanoma. 1 , 2 The complete version of the NCCN Guidelines for H&N Cancers is available at NCCN.org . Updates to these guidelines for 2014 include revisions to “Principles of Radiation Therapy” for each site and “Principles of Surgery
Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda
. Case 1 A 66-year-old Ashkenazi Jewish woman with a past medical history of early-stage invasive ductal carcinoma of the left breast, treated definitively with surgery and adjuvant tamoxifen therapy, presented after a routine colonoscopy revealed a 1
Michael P. Porter and Paul H. Lange
Vermooten V . Indications for conservative surgery in certain renal tumors: Study based on growth pattern of clear cell carcinoma . J Urol 1950 ; 64 : 200 – 208 . 5 Zinman L Dowd JB . Partial nephrectomy in renal cell carcinoma . Surg Clin
Angela Jain, Paula D. Ryan, and Michael V. Seiden
for craniectomies, and each lesion was excised over 2 different surgeries. This was followed by whole brain radiation. Figure 1 Liver metastases (A) pretreatment, (B) post FOLFOX (5-FU, leucovorin, and oxaliplatin) and bevacizumab, and (C) post
Pamala A. Pawloski, Gabriela Vazquez-Benitez, Jeanette Y. Ziegenfuss, Terese A. DeFor, and Elisabeth M. Seburg
and medical records. Time from diagnosis to surgery, chemotherapy, and radiation was measured in weeks and censored when disenrollment, death, or the end of the study period occurred. We assessed patient factors associated with time to chemotherapy
Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell, and Stephen Leong
Background: At our institution, the standard treatment recommendation for esophageal cancer patients with stage IB–IIIB disease is for neoadjuvant chemoradiation per the CROSS regimen prior to surgery. This regimen can be difficult for patients to
